PCM
SGMO

Prelude Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Prelude Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.3K Sell
53,779
-9,496
-15% -$3.78K ﹤0.01% 1168
2025
Q4 		$26.6K Sell
63,275
-36,041
-36% -$19.1K ﹤0.01% 1253
2025
Q3 		$66.9K Buy
+99,316
New +$53.5K 0.01% 1090
2025
Q2 		– Sell
-34,382
Closed -$22.5K – 1311
2025
Q1 		$22.5K Buy
+34,382
New +$36.4K ﹤0.01% 1128
2020
Q1 		– Sell
-276
Closed -$2K – 1974
2019
Q4 		$2K Sell
276
-48
-15% -$441 ﹤0.01% 1833
2019
Q3 		$3K Sell
324
-39
-11% -$438 ﹤0.01% 1603
2019
Q2 		$4K Sell
363
-425
-54% -$4.52K ﹤0.01% 1542
2019
Q1 		$8K Buy
+788
New +$8.05K ﹤0.01% 1541
2018
Q4 		– Sell
-42,759
Closed -$725K – 2124
2018
Q3 		$725K Hold
42,759
– – 0.04% 436
2018
Q2 		$607K Buy
42,759
+42,541
+19,514% +$707K 0.04% 475
2018
Q1 		$4K Sell
218
-370
-63% -$7.91K ﹤0.01% 1427
2017
Q4 		$10K Sell
588
-762
-56% -$11.3K ﹤0.01% 1206
2017
Q3 		$20K Sell
1,350
-813
-38% -$8.99K ﹤0.01% 1321
2017
Q2 		$19K Buy
+2,163
New +$13.9K ﹤0.01% 1273
2015
Q4 		– Sell
-3,517
Closed -$20K – 1660
2015
Q3 		$20K Sell
3,517
-983
-22% -$8.11K ﹤0.01% 1249
2015
Q2 		$50K Buy
4,500
+1,700
+61% +$21.9K 0.01% 1148
2015
Q1 		$44K Sell
2,800
-4,400
-61% -$68.1K 0.01% 1368
2014
Q4 		$110K Buy
+7,200
New +$87.4K 0.02% 963
2014
Q1 		– Sell
-2,700
Closed -$38K – 2082
2013
Q4 		$38K Hold
2,700
– – 0.01% 1132
2013
Q3 		$28K Sell
2,700
-4,076
-60% -$40.5K ﹤0.01% 1188
2013
Q2 		$53K Buy
+6,776
New +$59.1K 0.01% 815

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Prelude Capital Management's SGMO Position: Q1 2026 in Review

Prelude Capital Management reduced its SANGAMO THERAPEUTICS INC (SGMO) stake by 15% in Q1 2026, selling an estimated $3.78K and leaving 53,779 shares worth $13.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1168.

Prelude Capital Management first reported a position in SGMO in Q2 2013 and has held it in 21 quarters since. The position peaked at $725K in Q3 2018. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Prelude Capital Management held 53,779 shares of SANGAMO THERAPEUTICS INC worth $13.3K as of Q1 2026.
  • Prelude Capital Management sold 9,496 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $3.78K.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1168 holding.
  • Prelude Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and has held it in 21 quarters since.
  • Prelude Capital Management's SANGAMO THERAPEUTICS INC position peaked at $725K in Q3 2018.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.